Together, PharmOptima and Ophthy-DS will leverage their complimentary expertise to offer pharmaceutical companies a single reliable source for ocular drug discovery, development, safety, and pharmacokinetics. With this agreement, clients will gain increased access to an integrated portfolio of drug discovery services—from target validation and assay development to identification and optimization of clinical candidates.

For over a decade, Ophthy-DS has provided pharmacology models of ocular disease including Age Related Macular Degeneration (AMD), Glaucoma, Uveitis, Dry Eye, Corneal Injury, and Retinitis Pigmentosa. Utilizing clinical endpoints such as electroretinography (ERG), visual acuity, and ocular imaging including Optical coherence tomography (OCT), angiography and confocal scanning laser ophthalmoscopy (cSLO), Ophthy-DS has helped clients translate findings from bench to bedside. With an on-staff veterinary ophthalmologist and industry-trained scientists, Ophthy-DS offers a wide range of experience to elevate both the efficacy and safety of a wide range of therapies.  

“Using our years of Pharma experience, we help companies move their projects through development as if they were our own projects. We have been on your side of the desk and understand the needs of the development process,” says Dr. Jeff Jamison, chief executive officer of Ophthy-DS. “This new agreement will fortify what we can offer our clients, allowing them to do PK in parallel with efficacy testing.”